Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

The FDA has approved daratumumab and hyaluronidase (DARA SC; Darzalex Faspro, Janssen Biotech) for adults with high-risk ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

For the first time in more than a decade, a new frontline treatment for an incurable blood cancer is being added to the ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...

Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients ...